Department of Chemistry and Chemical Engineering, Wuhan University of Science and Technology, Wuhan City, Hubei Province 430081, P. R. China.
School of Molecular Sciences, Arizona State University, Tempe, Arizona 85287-1604, United States.
Anal Chem. 2021 Apr 20;93(15):6053-6061. doi: 10.1021/acs.analchem.0c04112. Epub 2021 Apr 5.
Increasing evidence has demonstrated that cells are individually heterogeneous. Advancing the technologies for single-cell analysis will improve our ability to characterize cells, study cell biology, design and screen drugs, and aid cancer diagnosis and treatment. Most current single-cell protein analysis approaches are based on fluorescent antibody-binding technology. However, this technology is limited by high background and cross-talk of multiple tags introduced by fluorescent labels. Stable isotope labels used in mass cytometry can overcome the spectral overlap of fluorophores. Nevertheless, the specificity of each antibody and heavy-metal-tagged antibody combination must be carefully validated to ensure detection of the intended target. Thus, novel single-cell protein analysis methods without using labels are urgently needed. Moreover, the labeling approach targets already known motifs, hampering the discovery of new biomarkers relevant to single-cell population variation. Here, we report a combined microfluidic and matrix-assisted laser desorption and ionization (MALDI) mass spectrometric approach for the analysis of protein biomarkers suitable for small cell ensembles. All necessary steps for cell analysis including cell lysis, protein capture, and digestion as well as MALDI matrix deposition are integrated on a microfluidic chip prior to the downstream MALDI-time-of-flight (TOF) detection. For proof of principle, this combined method is used to assess the amount of Bcl-2, an apoptosis regulator, in metastatic breast cancer cells (MCF-7) by using an isotope-labeled peptide as an internal standard. The proposed approach will eventually provide a new means for proteome studies in small cell ensembles with the potential for single-cell analysis and improve our ability in disease diagnosis, drug discovery, and personalized therapy.
越来越多的证据表明,细胞是个体异质性的。推进单细胞分析技术将提高我们描述细胞、研究细胞生物学、设计和筛选药物以及辅助癌症诊断和治疗的能力。目前大多数单细胞蛋白质分析方法都基于荧光抗体结合技术。然而,这种技术受到荧光标记物引入的高背景和多重标签交叉干扰的限制。质谱流式细胞术中使用的稳定同位素标记可以克服荧光团的光谱重叠。然而,必须仔细验证每个抗体和重金属标记抗体组合的特异性,以确保检测到预期的目标。因此,迫切需要新的无标记单细胞蛋白质分析方法。此外,标记方法针对的是已知的基序,阻碍了与单细胞群体变化相关的新生物标志物的发现。在这里,我们报告了一种结合微流控和基质辅助激光解吸电离(MALDI)质谱的方法,用于分析适合小细胞集合的蛋白质生物标志物。细胞分析所需的所有步骤,包括细胞裂解、蛋白质捕获和消化以及 MALDI 基质沉积,都在微流控芯片上集成,然后进行下游 MALDI-飞行时间(TOF)检测。为了验证原理,该联合方法用于通过使用同位素标记肽作为内标来评估转移性乳腺癌细胞(MCF-7)中凋亡调节剂 Bcl-2 的量。该方法最终将为小细胞集合中的蛋白质组学研究提供一种新的手段,具有单细胞分析的潜力,并提高我们在疾病诊断、药物发现和个性化治疗方面的能力。